New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
source: pixabay.com

New Combination for HRD-Positive Ovarian Cancer Gets EU Approval

According to a story from Cancer Network, the European Commission has recently approved a two-part combination treatment for advanced, homologous recombination deficiency (HRD)-positive ovarian cancer. This first-line maintenance treatment consists…

Continue Reading New Combination for HRD-Positive Ovarian Cancer Gets EU Approval

CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis

CymaBay Therapeutics, a biopharmaceutical company based in Newark, CA, develops and provides access to novel therapies with a recent focus on primary biliary cholangitis (PBC). The company is currently developing…

Continue Reading CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis
AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation
qimono / Pixabay

AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation

The FDA has recently granted the Rare Pediatric Disease (RPD) designation to AMO-02, a treatment for congenital myotonic dystrophy. As there is currently an unmet medical need for this condition,…

Continue Reading AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation
Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
source: pixabay.com

Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…

Continue Reading Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
Hereditary Angioedema Patients in the UK Get Early Access to New Treatment
source: pixabay.com

Hereditary Angioedema Patients in the UK Get Early Access to New Treatment

According to a story from GlobeNewswire, the company BioCryst Pharmaceuticals, Inc., recently announced that its drug berotralstat (marketed as Orladeyo) will be available in the UK under the Early Access…

Continue Reading Hereditary Angioedema Patients in the UK Get Early Access to New Treatment
Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU
source: pixabay.com

Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU

According to a story from Street Insider, the biopharmaceutical company Forma Therapeutics Holdings, Inc., recently announced that its investigational therapy candidate FT-4202 has earned Orphan Drug designation from the European…

Continue Reading Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU
EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
stevepb / Pixabay

EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment

The European Medicines Agency has accepted Biogen's Marketing Authorization Application (MAA) for review. The application is for aducanumab, a treatment for Alzheimer's disease. As this condition faces an unmet medical…

Continue Reading EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials
source: pixabay.com

Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials

In a press release from Sanofi, a global biopharmaceutical company, the company's experimental therapy candidate olipudase alfa has demonstrated the ability to substantially improve spleen volume and lung function in…

Continue Reading Experimental Treatment for Acid Sphingomyelinase Deficiency Shows Potential in Trials
The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment
source: pixabay.com

The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment

According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…

Continue Reading The Drug Dupixent Shows Potential as an Eosinophilic Esophagitis Treatment